Integrated Annual Report

Overview

The report presents Aurobindo Pharma's FY23 integrated performance, including consolidated revenue of ₹24,855 crore and continued expansion across pharmaceutical markets. It highlights a 17% reduction in carbon emissions from the FY20 baseline, consumption of 80,341 MWh of renewable power, and progress toward the 2025 renewable-energy goal. The report also describes a global workforce of more than 33,000 people and extensive community, healthcare, education, and rural-development initiatives. Sustainability disclosures cover materiality, climate and energy, water, waste, workforce diversity, occupational safety, and Board-level ESG oversight.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2022-2023
Period: 1 April 2022 – 31 March 2023
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Ratings

CDP score

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services